Atopic dermatitis is a chronic inflammatory skin condition. Credit: Kmpzzz / Shutterstock.

Castle Biosciences has reported preliminary data from its ongoing study of an atopic dermatitis (AD) pipeline test for individuals with moderate-to-severe conditions.

The test aims to detect patients more likely to achieve a ‘super response’ to targeted therapies, marked by a 90% or greater decrease in disease severity as per the Eczema Area and Severity Index (EASI) score within three months.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

With over 1,100 subjects enrolled across 39 clinical study sites, the company is developing and validating this study.

By detecting the immune pathways driving the disease, the test could lead to ‘effective’ treatment strategies, reducing the current ‘trial-and-error’ method. The company anticipates launching the test by the end of next year.

Castle Biosciences president and CEO Derek Maetzold said: “It is estimated that there are more than six million patients diagnosed with moderate-to-severe AD in the US seeking treatment annually, and approximately 760,000 of these patients seek systemic treatment.

“Today, once a clinician and patient determine that systemic therapy is needed to control the patient’s AD, a ‘trial-and-error’ treatment cycle begins. This ‘trial-and-error’ approach results in approximately 25% of patients discontinuing their initial systemic therapy. Separately, approximately 50% of patients who stay on their initial therapy have indicators of persistent disease burden.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The test analyses gene expression offering a precision medicine tool to improve patient outcomes and reduce healthcare resource utilisation.

Castle is currently planning the launch strategy for its test, which includes determining the reimbursement pathway.